Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
about
Imaging of liver cancer.Magnetic Nanoparticles in Cancer TheranosticsNanoparticle-based systems for T(1)-weighted magnetic resonance imaging contrast agentsNew magnetic resonance imaging methods in nephrologyNon-echoplanar diffusion weighted imaging in the detection of post-operative middle ear cholesteatoma: navigating beyond the pitfalls to find the pearlDouble agents and secret agents: the emerging fields of exogenous chemical exchange saturation transfer and T2-exchange magnetic resonance imaging contrast agents for molecular imagingAdvances in Magnetic Resonance Imaging Contrast Agents for Biomarker DetectionA single diamagnetic catalyCEST MRI contrast agent that detects cathepsin B enzyme activity by using a ratio of two CEST signalsDetection of Sulfatase Enzyme Activity with a CatalyCEST MRI Contrast AgentUltrasound Contrast Agents in the Study of Kidney Function in Health and Disease.Adenosine stress cardiovascular magnetic resonance-observation unit management of patients at intermediate risk for acute coronary syndrome: a possible strategy for reducing healthcare-related costs.Design of superparamagnetic nanoparticles for magnetic particle imaging (MPI).Molecular imaging of inflammation and intraplaque vasa vasorum: a step forward to identification of vulnerable plaques?Coronary microvascular resistance: methods for its quantification in humansCoronary computed tomography and magnetic resonance imagingInorganic nanoparticle-based T1 and T1/T2 magnetic resonance contrast probes.Residual analysis of the water resonance signal in breast lesions imaged with high spectral and spatial resolution (HiSS) MRI: a pilot study.Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors.Preliminary assessment of dispersion versus absorption analysis of high spectral and spatial resolution magnetic resonance images in the diagnosis of breast cancer.Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options.Simultaneous static and cine nonenhanced MR angiography using radial sampling and highly constrained back projection reconstruction.Scleroderma MimickersChallenges for Molecular Neuroimaging with MRI.Prognostic value of blood flow measurements using arterial spin labeling in gliomasNephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006.Relaxivity of gadolinium complexes detected by atomic magnetometry.Quasi-cubic magnetite/silica core-shell nanoparticles as enhanced MRI contrast agents for cancer imagingQuiescent-interval single-shot unenhanced magnetic resonance angiography of peripheral vascular disease: Technical considerations and clinical feasibility.In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model.Strategies for reducing respiratory motion artifacts in renal perfusion imaging with arterial spin labeling.Non-contrast enhanced MR angiography: physical principles.Arterial spin labeling MRI for assessment of perfusion in native and transplanted kidneys.Ungated radial quiescent-inflow single-shot (UnQISS) magnetic resonance angiography using optimized azimuthal equidistant projectionsVascular imaging: the evolving role of the multidisciplinary team meeting in peripheral vascular diseaseNephrogenic systemic fibrosis.Determination of the optimal first-order gradient moment for flow-sensitive dephasing magnetization-prepared 3D noncontrast MR angiography.Reproducibility of renal perfusion MR imaging in native and transplanted kidneys using non-contrast arterial spin labeling.Evaluation of peripheral arterial disease with nonenhanced quiescent-interval single-shot MR angiography.Measurement of T1 relaxation time of osteochondral specimens using VFA-SWIFT.Non-contrast-enhanced MR angiography at 3 Tesla in patients with advanced peripheral arterial occlusive disease.
P2860
Q24654739-2D2D61CE-0552-456B-9474-7CE09022CCEBQ26784379-4E155A68-0606-424A-A180-CBDC32B1C7C7Q26824262-4095D254-BE9F-4CCB-A6E8-6D7C7E00BA2DQ26866166-D9A1AF5E-5848-4A28-939D-B9FE13ECE53FQ28066231-C731936C-8064-45BB-A6F6-9B2716D8E326Q28822002-024F2CCC-E1F2-4DF7-B503-548DC2D31EE3Q28830010-F6EF0758-F10F-42E6-BB53-66BBC6C59145Q28833260-F853A64C-9360-4BCC-B3DF-8D4EFE83A011Q28833645-03E5887F-9679-42CC-AD81-913820D680EDQ30440590-6858A0E1-C19E-48C1-9ACB-4B4B815E3338Q30447598-A3446FBA-A2D5-4975-BE64-4E611447B14BQ30448145-6A4D1B17-69ED-4922-B6E6-41B44B443060Q30479243-C42F862D-D1A9-4635-84ED-E1EE45C851FAQ30487553-58A16210-AE65-4286-BB8F-AF04A1238953Q30488320-119343A8-2C0E-4CB5-A464-0548194378E1Q30564493-9232AE5E-D752-4C79-A4CA-B4B643C9C81BQ30725785-5638F740-1770-4C3A-B62F-C63A75AEA608Q30930526-BC3335FA-F0E3-48AD-9BDC-844056DF1FECQ30979450-017DBD7F-C464-4D99-BA3B-4536A29DF61EQ33168881-7EFFC17C-BAD4-4973-8CFA-8DFAB4984C41Q33594646-88855794-9E9C-4B56-AE2F-20233B459A85Q33625658-319AA4BF-E741-4570-9FFA-2E58AAE352FBQ33680025-E2033389-F1A0-4CB7-9B57-B051B60481DBQ33727772-40D69608-BA04-48D0-A4E5-78DEE89E9A6EQ33805280-0E4964A9-56AD-4634-9F7F-B1E59FA17620Q33854303-DDD596DD-FFB9-4376-9124-DE4E7108362EQ33958115-05CF3658-635D-45E5-A8EB-B0DA5B53755EQ33958220-FCDBE056-36FB-4FE3-9A6A-4E38DDB2F2B1Q33973363-10F5E6DB-F914-4E4E-BC07-78E504F24C74Q34157996-1E4850EA-825E-435E-8869-F80A8E43E2BFQ34288795-F4E1AD88-0FEE-4469-BF63-4C576CD1CC30Q34424299-C4ED4E3E-EDAF-4DA2-AF92-7E5183D4C495Q34498557-547261C6-0146-41B8-B584-ECCEEEE929ADQ34513844-974DB798-D8EC-4E0F-9712-B70B872B81D4Q34519247-481DDC66-BF66-4CFB-9609-BB86FAB5FBAFQ34794102-8AB05D5F-6C90-45A9-B48A-2DF931DA4438Q34993933-B3DECB57-D5B5-498B-A885-14B0D6ED10A3Q35062100-3EE11B60-DE69-4AC2-86B8-9C6ADB3089D2Q35072533-E3B54A67-0D51-472F-B380-2B9D90320D62Q35114860-51730DDE-39D4-4A90-87E5-A7769A618A05
P2860
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
@en
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
@nl
type
label
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
@en
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
@nl
prefLabel
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
@en
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
@nl
P2093
P1433
P1476
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
@en
P2093
Ali K Abu-Alfa
Emanuel Kanal
Phillip H Kuo
Shawn E Cowper
P304
P356
10.1148/RADIOL.2423061640
P407
P577
2007-01-09T00:00:00Z